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Will a Fixed Price Reimbursement Policy for Statins be Cost-Effective for Turkey’s Health 
Care System?  
 
Guvenc Kockaya, MD1, Albert I. Wertheimer, PhD2 
1Istanbul University, Istanbul Medicine Faculty, Pharmacology and Clinical Pharmacology Department 
2Temple University, School of Pharmacy, Center for Pharmaceutical Health Services Research 
 
The Social Security & Health section of the Turkish Statistical 
Institute (http://www.turkstat.gov.tr/) is the largest 
reimbursement foundation in Turkey covering nearly 70% of 
all health expenses for that country (www.tuik.gov.tr). In 
December 2009, the Social Security & Health foundation was 
scheduled to begin a fixed price reimbursement policy for 
several classes of medications, including the statin category, 
with the goal of reducing expenses.  However, pharmacist 
associations and pharmaceutical companies raised concerns 
about the approach because of the proposed decreases in 
reimbursement to both pharmacies and pharmaceutical 
manufacturers. In light of the concerns, the fixed price 
reimbursement policy was delayed.  
 
In the past, evaluation of statins’ cost-effectiveness has 
included assessment of the prevalence and incidence of 
diseases treated by statins [1,2], costs of morbidity and 
mortality of these diseases [1,2], relative effectiveness and 
safety of statins compared to other treatment options [1-8], 
and the relative cost-effectiveness of available statins in 
comparison to each other [2,7]. The cost-effectiveness 
evaluation conducted by Kockaya, et al. [2] was specific to 
family practice in Turkey and is particularly germane to the 
discussion in this commentary 
(http://www.scirp.org/journal/HEALTH/).   
 
The evaluations just described are extremely useful for 
decision-making, but typically are made under the 
assumptions that patients have adequate access to each 
compared medication and that the medications are used as 
directed in order to achieve outcomes similar to those 
identified through controlled clinical trials. We propose that, 
as fixed price reimbursement policies are designed and 
implemented, consideration must be given to how the 
policies would affect access to medications and patient 
adherence behaviors in light of out-of-pocket costs they may 
incur.  
 
For example, daily 10 mg rosuvastatin`s monthly treatment 
cost is nearly US$ 20 in Turkey. At the time this commentary 
was prepared, the Turkish Social Security & Health 
foundation paid approximately 80% of this amount leaving 
patient to pay only US$ 4 out-of-pocket for a one-month 
supply. However, if a fixed price reimbursement policy for 
statins is set at US$ 10 per month, this would leave US$ 10 for 
patients to pay out-of-pocket. This amount may be 
prohibitively expensive for many patients as Turkey`s 
monthly gross domestic product per capita is only US$ 750.  
 
We suggest that decisions regarding fixed price 
reimbursement policies must consider the effects of the 
policy on (1) the availability of medications (access) and (2) 
the out-of-pocket burden for patients. Such evaluations 
should include survey-based willingness-to-offer and 
willingness-to-pay analyses. Failure to consider these 
consequences of a fixed price policy could result in policies 
that decrease the amount spent on statins but increase costs 
associated with stroke, heart attack, and other cardiovascular 
diseases. Such evaluations also could help inform policy 
decisions regarding reimbursement and payment for statins 
that are used by particularly vulnerable populations. 
 
In conclusion, we propose that published cost-effectiveness 
analysis for statins can help inform decisions regarding fixed 
price policies regarding these medications. However, 
consideration must be given to how the policies would affect 
access to medications and patient adherence behaviors in 
light of out-of-pocket costs they may incur. We recommend 
that such evaluations should include survey-based 
willingness-to-offer and willingness-to-pay analyses. Failure 
to consider these consequences of a fixed price policy could 
result in policies that may decrease the amount spent on 
statins but would increase costs associated with stroke, heart 
attack, and other cardiovascular diseases. 
 
References 
1. Turkish Society of Cardiology [National Cardiology 
Health Politics], Turkish Society of Cardiology 
Antalya 2007 www.tkd.org.tr. 
2. Kockaya G, Wertheimer A, Daylan Kockaya P, Esen A. 
Considering the cost-effectiveness of statins in 
Family Practice in Turkey from a payer perspective. 
Health 2009; 1(4): 274-80. 
3. The Scandinavian Simvastatin Survival Study Group.  
Randomised trial of cholesterol lowering in 4444 
patients with coronary heart disease; the 
Commentary POLICY 
 
http://z.umn.edu/INNOVATIONS                          2010, Vol. 1, No. 2, Article 19                      INNOVATIONS in pharmacy   2 
 
Scandinavian Simvastatin Survival Study (4S). Lancet 
1994; 344:1383-9. 
4. Boyacı B. Cardiometabolic risk management: statins 
in the prevention of cardiovascular events   Turkiye 
Klinikleri J Med Sci 2008; 28(6 Suppl. 1):S44-7. 
5. Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of 
the statins in patients after acute myocardial 
infarction: does evidence chance practice? Arch 
Intern Med 2001; 161:183-8. 
6. Lemaitre RN, Furberg CD, Newman AB, Hulley SB, 
Gordon DJ, Gottdiener JS et al. Time trends in the 
use of cholesterol-lowering agents in older adults. 
Arch Intern Med 1998; 158:1761-6. 
7. Benner, J.S., Smith, T.W., Klingman, D., Tierce, J.C., 
Mullins, C.D., Pethick, N., et al. (2005) Cost effective-
ness of rosuvastatin compared with other statins 
from a managed care perspective value in health, 
8(6), 618-628.  
8.  Mora S, Glynn RJ, Hsia J, Macfadyen JG, Genest J, 
Ridker PM. Statins for the Primary Prevention of 
Cardiovascular Events in Women With Elevated 
High-Sensitivity C-Reactive Protein or Dyslipidemia. 
Results From the Justification for the Use of Statins 
in Prevention: An Intervention Trial Evaluating 
Rosuvastatin (JUPITER) and Meta-Analysis of Women 
From Primary Prevention Trials. Circulation. 2010 
Feb 22. [Epub ahead of print] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
